

REMARKS

Favorable reconsideration is respectfully requested.

The claims are 1 to 17.

Applicants acknowledge with appreciation the indication of allowable subject matter in claims 12, 14 and 15. However, for reasons set forth below, it will be seen that all of the claims in this application are now in condition for allowance.

With regard to the rejection of claim 13 as indefinite in the term "derivative", such term has been deleted, per the Examiner's suggestion.

With regard to the rejection of claim 16 as indefinite in the term "fused bicyclic pyridine derivative", the terminology suggested by the Examiner is now employed.

With regard to the objection to claims 17 to 25 as being substantial duplicates, claim 17 has been amended into the claim suggested by the Examiner and the remaining claims have been deleted.


No further issues remaining, allowance of this application is respectfully requested.

If the Examiner has any comments or proposals for expediting prosecution, please contact undersigned at the telephone number below.

Respectfully submitted,

Shigeki SETO et al.

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEES FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975

By: 
Matthew M. Jacob
Registration No. 25,154
Attorney for Applicants

MJ/kes
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
September 27, 2005